Home >> Health >> Pharmacy >> Drugs and Medications >> O >> Omalizumab




Omalizumab (marketed under a title Xolair®) occurs as monoclonal antibody made by Genentech / Novartis and used inside the main in allergy-related asthma therapy, with a purpose of reducing hypersensitised hypersensitivity. A drug, which is administered subcutaneously, binds to immunoglobulin E (IgE), a substance normally related to allergic reaction whilst present inside high numbers in the person. Omalizumab works by blocking a receptor of IgE (FcεRI). This prevents IgE from attaching to a class action of histamine-producing cells known as mast cells and basophils, which are responsible eventually making a illness of the allergic reaction apparent. For this understanding, omalizumab is ordinarily known as an anti-IgE antibody.

Due to the want of sufficient trading tools on the long-long-run effectiveness & side results of the drug, omalizumab professional assistance is non however super most common, & may be expensive. In addition, whenever IgE can be a natural defense against bloodsucking diseases, professional assistance is normally non recommended when sleep in environments in which the presence of organisms is green.

Recent the food and drug administration suggests that IgE might play an important role in the body's recognition of cancer cells, then indescriminate blocking of IgE / receptor interaction might develop unforseen problems.

Notes
Karagiannis SNorth, Wang Q, East N, Burke F, Riffard S, Bracher MG, Thompson RG, Durham SR, Schwartz LB, Balkwill FR, Gould HJ. Activity of person monocytes inside IgE antibody-dependent surveillance & killing of ovarian tumour cells. Eur J Immunol 2003;33:1030-40. PMID 12672069.

Xolair: New Hope for Asthma and Allergy Sufferers
Article about this medication under development by Genentech, from Vanderbilt University.

The Johns Hopkins Gazette: May 10, 1999
Article about clinical testing of the experimental anti-allergy agent Anti-IgE, in a version called rhuMAb-E25.

FDA Approves Omalizumab (Xolair), a Recombinant Anti-IgE Antibody, to Treat Allergic Rhinitis and Allergic Asthma
June 2003 article on the drug's US approval. Includes information about results of clinical trials.

Xolair
Full prescribing information from RxList.

Xolair - FamilyDoctor.org
Information for patients in English or Spanish.






© 2005 GeneralAnswers.org